Proteon Therapeutics’ hemodialysis drug tests advance

07/21/2014 2:37 PM

07/21/2014 4:43 PM

A crucial step to bring new drugs to market has begun by Proteon Therapeutics for its lead product, a drug expected to improve treatment of patients with chronic kidney disease.

Proteon, founded in 2001 in Kansas City, has been developing PRT-201, a drug designed to reduce the failure of hemodialysis vascular access, a condition that often develops in patients.

The drug has received “fast track” and “orphan drug” designations from the U.S. Food and Drug Administration and has begun Phase 3 clinical testing. Random, double-blind, placebo-controlled trials will enroll 300 patients at about 30 hemodialysis centers in this test phase.

Diane Stafford/


Join the Discussion

The Kansas City Star is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere on the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Terms of Service